Characteristics of Patients with Follicular Ameloblastoma at Oral Surgery Department of Dr. Hasan Sadikin General Hospital 2019 - 2020
DOI:
https://doi.org/10.32553/ijmbs.v7i10.2738Keywords:
Follicular Ameloblastoma, Oral SurgeryAbstract
Introduction: Ameloblastoma is the most common odontogenic tumor. Ameloblastoma is an intermediate (borderline) tumor since it is benign but locally invasive with a high recurrence rate if the excision is incomplete. Radiologically it can be monocystic or polycystic and histopathologically shows different characteristics with the follicular as the most occurrence type.
Method: This research is a descriptive study using medical record data of patients who diagnosed with ameloblastoma. The population for this study were patients with a diagnosis of follicular type ameloblastoma from January 2019 to December 2020 at the Oral Surgery Department of Dr. Hassan Sadikin Hospital.
Result: The result shows ameloblastoma occurred in 62% of women (26 patients) and 38% of men (16 patients). The type of ameloblastoma was varies, as the follicular type was found in 24 cases (57%), followed by the plexiform type which was found in 16 cases (38%) and the mixed plexiform-follicular type was found in 2 cases (5%). The treatment shows the conservative management of ameloblastoma using the dredging method in 9 patients (21%). Radical management of these data involved marginal resection in 1 patient (2%), segmental resection in 18 patients (43%), hemimaxillectomy in 3 patients (7%), and hemimandibulectomy in 11 patients (26%)
Conclusion: ameloblastoma is more common in women than men. The follicular type is more common than plexiform or the mixed type of ameloblastoma. Based on the location of the ameloblastoma, the most common is the mandible. Radical surgery is the most common used for ameloblastoma management.
Keywords: Follicular Ameloblastoma, Oral Surgery
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 International Journal of Medical and Biomedical Studies

This work is licensed under a Creative Commons Attribution 4.0 International License.